What is a Conjugate Vaccine? - Creative Diagnostics

The development of conjugate vaccines represents a significant advancement in immunization technology. These vaccines are designed to protect against bacterial infections that use polysaccharide capsules as a defense mechanism. By enhancing immune responses, conjugate vaccines provide durable immunity, particularly for infants and individuals with weakened immune systems.

Concept and Mechanism of Conjugate Vaccines

Conjugate vaccines work by linking a weak bacterial polysaccharide antigen to a strong protein carrier. This binding process strengthens the immune response and improves the ability of polysaccharides to trigger immunity. The mechanism of conjugate vaccines involves:

Antigen Presentation: The conjugated protein attracts T-helper cells, which then activate B cells to produce high-affinity antibodies.
Immune Memory: Unlike plain polysaccharide vaccines, conjugate vaccines generate long-lasting immune memory, providing protection against future infections.
Herd Immunity: By reducing bacterial carriage in the nasopharynx, conjugate vaccines decrease disease transmission within communities.

Components of Conjugate Vaccines

A typical conjugate vaccine consists of:

Conjugate Vaccine	Protein carrier: Conjugate vaccines contain a strong immunogenic protein that boosts immune response which includes:	Diphtheria toxoid (D)
		Tetanus toxoid (T)
		CRM197 (non-toxic diphtheria toxin mutant)
		Meningococcal outer membrane protein complex (OMPC)
		Haemophilus influenzae protein D (HiD)
	Polysaccharide Antigen: The polysaccharide antigen comes from bacterial capsules which enable the immune system to identify pathogens.

Advantages and Disadvantages Compared to Other Vaccines

Advantages:

Enhanced Immunogenicity: Conjugate vaccines elicit stronger immune responses in infants and young children compared to polysaccharide vaccines.
Immunologic Memory: They activate T-helper cells, creating long-term immune defense.
Herd Immunity Effect: Reduced bacterial carriage leads to lower disease transmission rates.
Broad Age Range Effectiveness: Conjugate vaccines are effective across all age groups, including infants and seniors, while polysaccharide vaccines often fail to protect children under two years old.

Disadvantages:

Higher Cost: Conjugate vaccines are more expensive to produce than traditional polysaccharide vaccines.
Multiple Doses Required: Booster shots may be necessary to maintain protective immunity.
Complex Manufacturing Process: The conjugation process requires advanced biotechnological techniques.

Examples of Common Conjugate Vaccines

1. Haemophilus influenzae type b (Hib) Conjugate Vaccine

Hib bacteria cause severe infections such as meningitis and pneumonia. Early Hib vaccines using polysaccharides were ineffective in young children. The introduction of conjugate vaccines like PRP-T and PRP-CRM has significantly reduced global Hib disease cases.

2. Pneumococcal Conjugate Vaccine (PCV)

Streptococcus pneumoniae infections lead to pneumonia and meningitis, which can progress to sepsis. PCV7 initially targeted seven serotypes but was later expanded to PCV13 for broader protection. Conjugate pneumococcal vaccines have greatly reduced invasive pneumococcal disease in children and adults.

Figure 1. Schematic representation of the T-dependent mechanism of the PCV 13 vaccine. (Source: Scelfo C, et al.,2021)

3. Meningococcal Conjugate Vaccine

Neisseria meningitidis causes bacterial meningitis and sepsis. Traditional polysaccharide vaccines provided only short-term protection, especially in infants. The introduction of MenACWY and MenB conjugate vaccines has reduced meningococcal disease incidence across multiple serogroups.

4. Typhoid Conjugate Vaccine (TCV)

Salmonella Typhi bacteria cause typhoid fever. Unlike polysaccharide vaccines, TCV provides effective protection for young children, expanding coverage to vulnerable populations.

Applications in Research and Diagnostics

Research into conjugate vaccines has driven advancements in immunization methods and diagnostic testing. Conjugation techniques enhance antigen presentation in tools like ELISA kits and immunoassays, improving diagnostic accuracy. These methods also support the development of vaccines against challenging pathogens, further advancing public health efforts.

Conclusion

Conjugate vaccines have revolutionized disease prevention by addressing the limitations of polysaccharide vaccines. They provide long-lasting immunity and herd protection, safeguarding vulnerable populations such as infants and the elderly. Recent scientific advancements in conjugate vaccine technology have expanded protection to a broader range of bacterial diseases, underscoring their critical role in global health.

References

Pichichero ME. Protein carriers of conjugate vaccines: Characteristics, development, and clinical trials. Hum Vaccin Immunother. 2013;9(12):2505–2523.
Scelfo C, Menzella F, Fontana M, Ghidoni G, Galeone C, Facciolongo NC. Pneumonia and Invasive Pneumococcal Diseases: The Role of Pneumococcal Conjugate Vaccine in the Era of Multi-Drug Resistance. Vaccines. 2021;9(5):420.

Pathogenic Bacteria ELISA Kits

Target	Cat. No.	Product Name	Size	Species	Application	Detection Sample
S. enterica	DEIA8603	Salmonella Typhi IgM ELISA Kit	96T	Human	Quantitative	serum, plasma	Inquiry
Shiga Toxins	DEIASL162	Shiga toxins ELISA Kit	96T	Human	Qualitative	Fecal	Inquiry
S. aureus Enterotoxins	DEIA-CL032	Human Staphylococcus Aureus Enterotoxins (SE) ELISA Kit	48T, 96T	Human	Quantitative	serum, plasma, tissues Homogenate, Feces, urine, Body Fluids	Inquiry
E. coli	DEIA2348	E. Coli Verotoxin (Fecal) ELISA Kit	96T		Qualitative	stool supernatant	Inquiry
	DEIA2562	E.coli Antigen In Food ELISA Kit	96T		Quantitative	food	Inquiry
	DEIA2437	E.Coli O157 (Fecal) ELISA Kit	96T		Qualitative	feces	Inquiry
E. coli CAT	DEIA8703	CAT ELISA Kit	96T		Quantitative	eukaryotic cells	Inquiry
E. coli LPS	DEIA-LL289	LPS (Lipopolysaccharides) ELISA Kit	96T	Universal	Quantitative	Bacterial cell walls of gramnegative bacteria, tissue homogenates, other biological fluids	Inquiry
E. coli O157	DEIA-NS2402-6	E.coli O157 ELISAKit	96T	Human	Quantitative	ground beef, milk, lettuce, etc	Inquiry
E. coli Verotoxin (SLT-2b)	ABPR-ZB223	E.coli Shiga toxin II subunit B Antibody Pair Set	5 Plates, 15 Plates	E.coli	sELISA		Inquiry
E. granulosus	DEIA1777	Human Echinococcus granulosus IgG ELISA Kit	96T	Human	Semi-quantitative	Serum, plasma	Inquiry
	DEIA1095	Echinococcus IgG ELISA Kit	96T		Qualitative	serum	Inquiry
	DEIA1096	Echinococcus IgM ELISA Kit	96T		Qualitative	serum	Inquiry
E. histolytica	DEIA2309PY	Entamoeba histolytica Ag ELISA Kit	96T		Qualitative	stool	Inquiry
	DEIA1674	Human Entamoeba histolytica IgG (Amebiasis) ELISA kit	96T	Human	Qualitative	Human serum or plasma (citrate, heparin)	Inquiry
	DEIA7704	Entamoeba histolytica IgG ELISA Kit	96T	Human	Qualitative	serum, plasma	Inquiry
	DEIA2309PY-1	Entamoeba Ag ELISA Kit	96T	Human	Qualitative	Stool	Inquiry
E.coli HCP	DEIABL481	E.coli HCP ELISA kit	96T	E.coli	Quantitative	Host cells	Inquiry
	DEIA-HCP23-3	E.coli HCPs(E.coli host cell proteins) ELISA Kit	96T	N/A	Quantitative	biological products	Inquiry
	DEIA-JY2302	E.coli HCP (Alkaloid cleavage) ELISA Kit	96T		Quantitative	Biological samples	Inquiry
	DEIA-JY2303	E.coli HCP (Expression strain) ELISA	96T		Quantitative	Biological samples	Inquiry
	DEIABL481NS	E.coli HCP ELISA kit	96T	N/A	Quantitative	host cells	Inquiry
F. tularensis	DEIA-XY127	Francisella tularensis IgG ELISA Kit	96T	Human	Quantitative	serum, EDTA plasma, heparin plasma, citrate plasma	Inquiry
	DEIA-XY128	Francisella tularensis IgM ELISA Kit	96T	Human	Quantitative	serum, EDTA plasma, heparin plasma, citrate plasma	Inquiry
	DEIASL279	Human Anti-Francisella tularensis ELISA Kit	96T		Qualitative	Serum	Inquiry

Hib ELISA Kits

Target	Cat. No.	Product Name	Size	Species	Application	Detection Sample
H. influenza B	DEIA1650	Human Haemophilus Influenza B IgG ELISA Kit	96T	Human	Qualitative	serum, plasma	Inquiry
H. influenzae	DEIA599	HiB IgG ELISA Kit	96T	Human	Quantitative	serum, plasma	Inquiry
	DEIASL260	Mouse Anti-Haemophilus Influenzae B (HIB) IgG ELISA Kit	96T		Quantitative	Srerum	Inquiry
	DEIASL268	Rabbit Anti-Haemophilus Influenzae B (HIB) IgG ELISA Kit	96T		Quantitative	Srerum	Inquiry